BREXPIPRAZOLE
Total Payments
$3.4M
Transactions
397
Doctors
66
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $59,088 | 55 | 19 |
| 2017 | $3.3M | 342 | 52 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.3M | 320 | 98.0% |
| Consulting Fee | $46,033 | 27 | 1.4% |
| Travel and Lodging | $21,135 | 31 | 0.6% |
| Food and Beverage | $894.23 | 15 | 0.0% |
| Education | $711.92 | 2 | 0.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $118.98 | 2 | 0.0% |
Payments by Type
Research
$3.3M
320 transactions
General
$68,894
77 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A STUDY OF THREE FIXED-DOSES OF BREXPIPRAZOLE IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMER'S TYPE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $965,567 | 8 |
| SAFETY AND TOLERABILITY STUDY OF FLEXIBLE DOSING OF BREXPIPRAZOLE IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMER'S TYPE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $917,347 | 2 |
| A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BREXPIPRAZOLE PLUS KETAMINE IN TREATMENT-RESISTANT DEPRESSION TRD | Otsuka Pharmaceutical Development & Commercialization, Inc. | $874,859 | 0 |
| A STUDY OF FLEXIBLE-DOSE BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $312,494 | 1 |
| SAFETY FOLLOW-UP STUDY FOR SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMER'S TYPE WHO PREVIOUSLY PARTICIPATED IN A DOUBLE-BLIND TRIAL OF BREXPIPRAZOLE OR PLACEBO | Otsuka Pharmaceutical Development & Commercialization, Inc. | $105,803 | 3 |
| BREXPIPRAZOLE FOR BIPOLAR DEPRESSION | Otsuka Pharmaceutical Development & Commercialization, Inc. | $83,301 | 0 |
| A Phase 2, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial | Otsuka Pharmaceutical Development & Commercialization, Inc. | $37,466 | 32 |
| A 2-MONTH, OBSERVATIONAL, ROLLOVER TRIAL TO EVALUATE THE SAFETY OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMERS TYPE WHO WERE PREVIOUSLY TREATED WITH BREXPIPRAZOLE OPC-34712 OR PLACEBO IN A PHASE 3, DOUBLE-BLIND TRIAL | Otsuka Pharmaceutical Development & Commercialization, Inc. | $975.76 | 0 |
Top Doctors Receiving Payments for BREXPIPRAZOLE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Miami Springs, FL | $3.1M | 101 |
| , MD | Psychiatry | Sanford, FL | $49,864 | 2 |
| , MD | Neurology | Providence, RI | $26,856 | 3 |
| , M.D | Psychiatry | Raleigh, NC | $21,197 | 10 |
| , MD | Psychiatry | Waukesha, WI | $14,435 | 2 |
| , MD | Neurology | Indianapolis, IN | $11,985 | 3 |
| , M.D | Psychiatry | Gainesville, FL | $10,952 | 4 |
| , MD | Geriatric Psychiatry | Omaha, NE | $10,580 | 2 |
| , MD | Specialist | Carlsbad, CA | $4,797 | 18 |
| , M.D | Cardiovascular Disease | Jacksonville, FL | $4,027 | 4 |
| , MD | Geriatric Medicine | New York, NY | $3,796 | 5 |
| , MD | Psychiatry | Orange, CA | $3,612 | 4 |
| , M.D | Addiction Psychiatry | Baltimore, MD | $3,125 | 2 |
| , MD | Psychiatry | Bronx, NY | $2,952 | 2 |
| , MD | Psychiatry | Colorado Springs, CO | $1,838 | 7 |
| , D.O | Psychiatry | Fort Worth, TX | $1,591 | 1 |
| , MD | Psychiatry | Aventura, FL | $1,562 | 4 |
| , M.D., PH.D | Psychiatry | San Rafael, CA | $1,538 | 2 |
| , MD | Psychiatry | Glen Oaks, NY | $1,500 | 1 |
| , MD | Psychiatry | Barling, AR | $1,474 | 5 |
| , D.O | Psychiatry | Berlin, NJ | $1,455 | 7 |
| , M.D | Psychiatry | Costa Mesa, CA | $1,452 | 7 |
| , MD | Child & Adolescent Psychiatry | Memphis, TN | $1,413 | 7 |
| , M.D | Psychiatry | Lincoln, RI | $1,377 | 7 |
| , MD | Geriatric Psychiatry | Rochester, NY | $1,373 | 7 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.4M
- Total Doctors 66
- Transactions 397
About BREXPIPRAZOLE
BREXPIPRAZOLE is a drug associated with $3.4M in payments to 66 healthcare providers, recorded across 397 transactions in the CMS Open Payments database. The primary manufacturer is Otsuka Pharmaceutical Development & Commercialization, Inc..
Payment data is available from 2017 to 2018. In 2018, $59,088 was paid across 55 transactions to 19 doctors.
The most common payment nature for BREXPIPRAZOLE is "Unspecified" ($3.3M, 98.0% of total).
BREXPIPRAZOLE is associated with 8 research studies, including "A STUDY OF THREE FIXED-DOSES OF BREXPIPRAZOLE IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMER'S TYPE" ($965,567).